Format

Send to

Choose Destination
Nutr Diabetes. 2016 Dec 12;6(12):e237. doi: 10.1038/nutd.2016.49.

Kefir peptides prevent high-fructose corn syrup-induced non-alcoholic fatty liver disease in a murine model by modulation of inflammation and the JAK2 signaling pathway.

Author information

1
Department of Bioresources, Da-Yeh University, Changhwa, Taiwan.
2
Department of Life Sciences and Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.
3
Graduate Institute of Veterinary Pathology, National Chung Hsing University, Taichung, Taiwan.
4
Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
5
Rong-Hsing Translational Medicine Center, iEGG Center, National Chung Hsing University, Taichung, Taiwan.

Abstract

OBJECTIVE:

In recent years, people have changed their eating habits, and high-fructose-containing bubble tea has become very popular. High-fructose intake has been suggested to be a key factor that induces non-alcoholic fatty liver disease (NAFLD). Kefir, a fermented milk product composed of microbial symbionts, has demonstrated numerous biological activities, including antibacterial, antioxidant and immunostimulating effects. The present study aims to evaluate the effects of kefir peptides on high-fructose-induced hepatic steatosis and the possible molecular mechanism.

RESULTS:

An animal model of 30% high-fructose-induced NAFLD in C57BL/6J mice was established. The experiment is divided into the following six groups: (1) normal: H2O drinking water; (2) mock: H2O+30% fructose; (3) KL: low-dose kefir peptides (50 mg kg-1)+30% fructose; (4) KM: medium-dose kefir peptides (100 mg kg-1)+30% fructose; (5) KH: high-dose kefir peptides (150 mg kg-1)+30% fructose; and (6) CFM: commercial fermented milk (100 mg kg-1)+30% fructose. The results show that kefir peptides improve fatty liver syndrome by decreasing body weight, serum alanine aminotransferase, triglycerides, insulin and hepatic triglycerides, cholesterol, and free fatty acids as well as the inflammatory cytokines (TNF-α, IL-6 and IL-1β) that had been elevated in fructose-induced NAFLD mice. In addition, kefir peptides markedly increased phosphorylation of AMPK to downregulate its targeted enzymes, ACC (acetyl-CoA carboxylase) and SREBP-1c (sterol regulatory element-binding protein 1), and inhibited de novo lipogenesis. Furthermore, kefir peptides activated JAK2 to stimulate STAT3 phosphorylation, which can translocate to the nucleus, and upregulated several genes, including the CPT1 (carnitine palmitoyltransferase-1) involved in fatty acid oxidation.

CONCLUSION:

Our data have demonstrated that kefir peptides can improve the symptoms of NAFLD, including body weight, energy intake, inflammatory reaction and the formation of fatty liver by activating JAK2 signal transduction through the JAK2/STAT3 and JAK2/AMPK pathways in the high-fructose-induced fatty liver animal model. Therefore, kefir peptides may have the potential for clinical application for the prevention or treatment of clinical metabolic syndrome.

PMID:
27941940
PMCID:
PMC5223135
DOI:
10.1038/nutd.2016.49
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center